Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 9, 2026 4 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 MOST POPULAR Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... January 30, 2024 Diving into our role in 50 top cancer drugs February 9, 2022 Partnering with Small Business to Advance Innovation in Cancer Research and... February 21, 2019 Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... March 6, 2020 Load more HOT NEWS Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... Techniques for Successful Glucose Daddies and Babies Relationships
